Cohen Joshua B, CEO, reported an open-market or private sale at Amylyx Pharmaceuticals, Inc. involving 15500.000000 shares for an estimated $227592.70. Reported holdings after the transaction were 3363965.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
Form 4 relationship flags and nearby filing context
Co-Chief Executive Officer
Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock
units. Such sales were automatic and not at the discretion of the Reporting Person.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.510 to $14.760.
Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
0 other filings
0 recent txs